Nutlin-3b

• Description:

  Nutlin-3b, the inactive form of Nutlin-3 (HY-50696), is a p53/MDM2 inhibitor with an IC50 of 13.6 μM. Nutlin-3b is 150 times less potent in binding to MDM2 than Nutlin-3a (HY-10029) . Nutlin-3b is promising for research of cancers[1][2][3][4].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H319, H332, H372, H400

• Target:

  E1/E2/E3 Enzyme; MDM-2/p53

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Nutlin-3b.html

• Purity:

  98.78

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C1NCCN (C (N2[C@@H] (C3=CC=C (Cl) C=C3) [C@@H] (C4=CC=C (Cl) C=C4) N=C2C5=CC=C (OC) C=C5OC (C) C) =O) C1

• Molecular Formula:

  C30H30Cl2N4O4

• Molecular Weight:

  581.49

• Precautions:

  H302, H319, H332, H372, H400

• References & Citations:

  [1]Vassilev LT, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 Feb 6;303 (5659) :844-8.|[2]Müller CR, et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer. 2007 Jul 1;121 (1) :199-205.|[3]Michaelis M, et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res. 2009 Jan 15;69 (2) :416-21. |[4]Zhang F, et al. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem Pharmacol. 2011 Jul 1;82 (1) :24-34.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  675576-97-3